Document is current
Any future updates will be listed below
-
Authors
Kim, Kwanghee https://orcid.org/0000-0003-0544-6792
Hu, Wenhuo https://orcid.org/0000-0002-8686-7160
Audenet, François https://orcid.org/0000-0001-5722-2075
Almassi, Nima
Hanrahan, Aphrothiti J.
Murray, Katie https://orcid.org/0000-0002-2633-9438
Bagrodia, Aditya
Wong, Nathan
Clinton, Timothy N. https://orcid.org/0000-0002-0616-6840
Dason, Shawn
Mohan, Vishnu
Jebiwott, Sylvia
Nagar, Karan
Gao, Jianjiong
Penson, Alex https://orcid.org/0000-0003-2429-2370
Hughes, Chris
Gordon, Benjamin https://orcid.org/0000-0002-3856-0500
Chen, Ziyu
Dong, Yiyu
Watson, Philip A.
Alvim, Ricardo
Elzein, Arijh
Gao, Sizhi P.
Cocco, Emiliano
Santin, Alessandro D.
Ostrovnaya, Irina
Hsieh, James J. https://orcid.org/0000-0003-3595-0551
Sagi, Irit
Pietzak, Eugene J.
Hakimi, A. Ari https://orcid.org/0000-0002-0930-8824
Rosenberg, Jonathan E.
Iyer, Gopa https://orcid.org/0000-0002-5093-6099
Vargas, Herbert A.
Scaltriti, Maurizio https://orcid.org/0000-0002-5522-1447
Al-Ahmadie, Hikmat https://orcid.org/0000-0002-2938-6627
Solit, David B. https://orcid.org/0000-0002-6614-802X
Coleman, Jonathan A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA221745, R01 CA234361, P01 CA221757-01A1, P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 11 September 2019
Accepted: 24 March 2020
First Online: 24 April 2020
Competing interests
: M.S. is in the Advisory Board of Bioscience Institute and Menarini Ricerche, received research funds from Puma Biotechnology, Daiichi-Sankio, Targimmune, Immunomedics and Menarini Ricerche, is a co-founder of Medendi Medical Travel and in the past two years he received honoraria from Menarini Ricerche and ADC Pharma. E.J.P. is on the scientific advisory board for Merck. J.J.H. is a consultant of Eisai (RCC Strategic Council) (2018-2019) and received research funds from BostonGene (2019). D.B.S. has served as a consultant and received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Vivideon Therapeutics, Q.E.D. Therapeutics and Illumina. A.D.S. is in the Advisory Board of Merck and Tesaro, received research funds from R-Pharma, Gilead, Genentech, Boheringer, Puma Biotechnology and Immunomedics. The remaining authors declare no conflicts of interest.
